Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2021-02-08 Director's Dealing
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Director's Dealing 2021
Director's Dealing Classification · 100% confidence The document title explicitly states: "Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons." This directly describes insider trading activity or director's dealings. The filing category 'Director's Dealing (Code: DIRS)' matches this content perfectly. Although the document mentions attachments and is short (under 5,000 characters), suggesting it could be an RPA, the core subject matter is so specific to DIRS that it overrides the general RPA rule, as DIRS is a more specific classification than RPA or RNS. The content is the announcement *of* the director's dealing, which is the purpose of a DIRS filing.
2021-02-08 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for 'notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR). It identifies the individual (Matthew Donald Dallas, CFO), the issuer (Zealand Pharma A/S), and details a specific transaction (subscription of shares). This matches the definition for Director's Dealing (DIRS).
2021-02-08 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document follows the standard template for 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR). It identifies the CEO (Emmanuel Dulac) as the person discharging managerial responsibilities and details a subscription of shares. This is a classic insider transaction report, which falls under the 'Director's Dealing' category.
2021-02-08 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 98% confidence The document is a company announcement from Zealand Pharma regarding the completion and registration of a capital increase involving 3,600,841 new shares. This action directly relates to changes in the company's share structure and fundraising activities. The key phrases are 'completes registration of capital increase,' 'capital increase of 3,600,841 new shares,' and 'The New Shares have been issued.' This aligns perfectly with the definition of 'Capital/Financing Update' (CAP), which covers fundraising, financing activities, or capital structure changes. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV).
2021-02-01 English
Share Issue/Capital Change 2021
Share Issue/Capital Change Classification · 98% confidence The document is a company announcement detailing the completion of a 'directed issue and private placement of approx. 3.6 million new ordinary shares raising gross proceeds of approx. DKK 749 million'. This explicitly describes a capital raising and share issuance activity. This aligns directly with the definition of 'Capital/Financing Update' (CAP) or potentially 'Share Issue/Capital Change' (SHA). Since the core event is the issuance of new shares to raise capital, SHA is the most precise fit, as it covers 'new share issues' and 'capital changes'. The document is a full announcement, not just a notice of publication (RPA/RNS).
2021-01-27 English
Share Issue/Capital Change 2021
Share Issue/Capital Change Classification · 98% confidence The document is a company announcement titled "Zealand Pharma announces directed issue and private placement corresponding to approx. 10% of existing share capital." It details the launch of an offering of new shares through an accelerated bookbuilding process, specifying the use of proceeds, participation intentions of management, and the expected timetable for settlement and listing. This content directly relates to fundraising, capital structure changes, and the issuance of new shares. This aligns perfectly with the definition for Capital/Financing Update (CAP) or Share Issue/Capital Change (SHA). Since the core action is the issuance of new shares to raise capital, SHA is the most precise fit, as it covers 'new share issues' and 'capital changes'. The document is a full announcement, not just a notice of publication (RPA/RNS).
2021-01-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.